Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Mesothelioma

Trial Information

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma

Official Title: NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)

Summary

The main objective of the trial is to document the efficacy of NGR-hTNF administered as maintenance treatment at 0.8 µg/m2 weekly in advanced malignant pleural mesothelioma

Phase: Phase 2

Sponsor: MolMed S.p.A.

Overall Contacts:

Armando Santoro, MD
0

Locations (6)

Country State City Zip Facility and Contact
Italy Alessandria Casale Monferrato 15033 Ospedale Santo Spirito
Mario Botta, MD

Mario Botta, MD
Principal Investigator
Italy Milan Rozzano 20089 Istituto Clinico Humanitas

Armando Santoro, MD
Principal Investigator

Paolo Zucali, MD
Sub-Investigator
Italy Alessandria 15121 Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Federica Grosso, MD

Federica Grosso, MD
Principal Investigator
Italy Genova 16149 Asl 3 genovese, Ospedale Villa Scassi
Manlio Mencoboni, MD

Manlio Mencoboni, MD
Principal Investigator
Italy Pavia 27100 IRCCS Policlinico S. Matteo
Camillo Porta, MD

Camillo Porta, MD
Principal Investigator
Italy Treviso 31100 Ospedale Ca' Foncello
Giovanni Rosti, MD

Giovanni Rosti, MD
Principal Investigator

NCT ID:NCT01358084

Date Last Changed: January 28, 2013